Saturday 17 October 2026
Export CTEV’s income statement to Excel — free account
Claritev Corporation
CTEV Healthcare Health Information Services
Claritev Corporation’s revenue for fiscal 2025 (year ended December 2025) was $965.4 million, up 3.74% from fiscal 2024. In the quarter to June 2026, revenue grew 6.59%, EPS grew 8.40%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
22.12
1.74
−7.29%
Follow CTEV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.58 | 0.28 | 0.73 | 0.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
6.24 | (5.96) | 10.60 | 44.06 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.25 | 5.06 | 5.46 | 5.74 | |
EV/EBITDA |
10.75 | 10.30 | 10.92 | 12.20 | |
EV/Operating CF |
39.27 | 48.74 | 44.91 | 309.53 | |
EV/FCF |
(291.44) | (137.93) | (429.21) | (48.49) | |
Quick Ratio |
0.67 | 0.93 | 0.60 | 0.83 | |
Current Ratio |
1.00 | 1.28 | 0.86 | 1.21 | |
Net Debt/EBITDA |
34.09 | 39.05 | 43.01 | 37.05 | |
Debt/Assets |
98.09% | 97.41% | 94.00% | 92.81% | |
Debt/Equity |
(16.23) | (20.11) | (27.49) | (45.48) | |
Asset Turnover |
0.20 | 0.20 | 0.19 | 0.18 | |
Operating CF/Net income |
(1.56) | 0.62 | (0.82) | (0.28) | |
Capex/Depreciation |
(0.34) | (0.41) | (0.26) | (0.32) | |
Interest Coverage |
0.23 | 0.07 | (0.08) | 0.10 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
21.51% | 23.64% | 24.96% | 25.16% | |
Intangible Assets out of Total Assets |
0.86 | 0.87 | 0.88 | 0.88 | |
Share Based Compensation of Revenue |
2.86% | 2.82% | 3.16% | 2.84% | |
Graham Net Nets |
(8.32) | (17.71) | (6.88) | (5.53) | |
Graham Number |
80.58 | 74.00 | 62.92 | 53.92 | |
Earnings Yield |
(49.87%) | (106.06%) | (40.47%) | (39.39%) | |
Free Cash Flow Yield |
(3.10%) | (13.16%) | (1.75%) | (12.86%) | |
Revenue per Share |
15.18 | 14.66 | 15.00 | 14.92 | |
Operating CF per Share |
5.46 | (2.74) | 4.03 | 1.20 | |
Capex per Share |
(2.24) | (2.80) | (1.82) | (2.20) | |
Free Cash Flow per Share |
3.22 | (5.54) | 2.21 | (0.99) | |
Cash per Share |
1.63 | 2.08 | 1.72 | 3.07 | |
Shareholders Equity per Share |
(16.97) | (14.04) | (10.17) | (6.18) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(16.97) | (14.04) | (10.17) | (6.18) | |
Free Cash Flow |
54.59 | (92.55) | 36.38 | (16.35) | |
Working Capital |
(1.09) | 52.70 | (36.99) | 44.14 | |
Capital Expenditures |
(38.08) | (46.77) | (29.91) | (36.20) | |
Net Current Asset Value |
(4,815.28) | (4,831.45) | (4,831.27) | (4,834.68) | |
EV/EBIT |
160.77 | 192.97 | 183.19 | 0.00 | |
Capex to Sales |
0.15 | 0.19 | 0.12 | 0.15 | |
Price to Operating Income |
17.81 | 10.63 | 24.43 | 0.00 | |
| Other line items | |||||
Average Receivables |
127.24 | 117.19 | 108.69 | 104.56 | |
Average Payables |
50.05 | 46.84 | 73.40 | 30.74 | |
Average Assets |
4,917.92 | 4,961.91 | 5,019.64 | 5,154.75 | |
Average Common Equity |
(163.87) | (109.79) | (41.58) | 52.86 |
Columns are period end dates